Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Oike, Takahiro ^a   Suzuki, Yoshiyuki ^a   Sugawara, Ken Ichi ^a   Shirai, Katsuyuki ^a   Noda, Shin Ei ^a   Tamaki, Tomoaki ^a   Nagaishi, Masaya ^a   Yokoo, Hideaki ^a   Nakazato, Yoichi ^a   Nakano, Takashi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; JAPANESE; LEUKOPENIA; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RADIATION DOSE FRACTIONATION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; CHEMORADIOTHERAPY; CHILD; CHILD, PRESCHOOL; DACARBAZINE; FEASIBILITY STUDIES; FEMALE; GLIOBLASTOMA; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84893412858     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078943     Document Type: Article

References (23)

1. Suzuki Y, Shirai K, Oka K, Mobaraki A, Yoshida Y, et al. (2010) Higher pAkt expression predicts a significant worse prognosis in glioblastomas. J Radiat Res 51: 343-348.
2. Louis DN, Ohgaki H, Weistler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109. (Pubitemid 47103521)
3. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, et al. (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323-1329. (Pubitemid 11194457)
4. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466.
7. Nagaishi M, Yokoo H, Hirato J, Yoshimoto Y, Nakazato Y (2012) Clinicopathological feature of pilomyxoid astrocytomas: three case reports. Neuropathology 31: 152-157.
8. Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussiere M, et al. (2012) Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNAmethyltranferase in a series of 100 glioblastoma patients. Cancer 118: 4201-4211.
9. Tanaka G, Nakazato Y (2004) Automatic quantification of the MIB-1 immunoreactivity in brain tumors. Int Congr Ser 1259: 15-19.
10. Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4: 296-307.
11. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003. (Pubitemid 40349502)
12. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, et al. (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27: 5743-5750.
13. Chinot OL, Barrie M, Fuentes S, Eudes N, Lancelot S, et al. (2007) Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25: 1470-1475. (Pubitemid 46733073)
14. Preusser M, Janzer RC, Felsberg J, Reifenberger G, Hamou MF, et al. (2008) Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18: 520-532.
15. Tang K, Jin Q, Yan W, Zhang W, You G, et al. (2012) Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients. Med Oncol 29: 1292-1296.
16. Brown DC, Gatter KC (2002) Ki67 protein: the immaculate deception? Histopathology 40: 2-11. (Pubitemid 34107377)
17. Colleoni M, Zarieh D, Gelber RD, Viale G, Luini A, et al. (2003) Preoperative systemic treatment: prediction of responsiveness. Breast 12: 538-542. (Pubitemid 38008670)
18. Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, et al. (1997) Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 86: 121-130. (Pubitemid 27009983)
19. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, et al. (2005) Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23: 2372-2377. (Pubitemid 46218731)
20. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, et al. (2009) Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27: 579-584.
21. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, et al. (2011) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29: 142-148.
22. Tsien CI, Brown D, Normolle D, Schipper M, Piert M, et al. (2012) Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. Clin Cancer Res 18: 273-279.
23. Iuchi T, Hatano K, Narita Y, Kodama T, Yamaki T, et al. (2006) Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys 64: 1317-1324.